All data are based on the daily closing price as of November 18, 2026
s
Shin Nippon Biomedical Laboratories
2395.TSE
7.26 USD
-0.13
-1.76%
Overview
Last close
7.26 usd
Market cap
302.41M usd
52 week high
12.51 usd
52 week low
6.72 usd
Target price
10.63 usd
Valuation
P/E
8.5817
Forward P/E
N/A
Price/Sales
1.3847
Price/Book Value
1.2818
Enterprise Value
470.82M usd
EV/Revenue
2.1228
EV/EBITDA
6.3373
Key financials
Revenue TTM
221.79M usd
Gross Profit TTM
115.04M usd
EBITDA TTM
48.30M usd
Earnings per Share
0.86 usd
Dividend
0.19 usd
Total assets
696.50M usd
Net debt
155.45M usd
About
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.